Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06090591

Cardiology Research Dubrava Prospective Registry

Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Heart Failure Acute Coronary Syndrome Arrhythmias, Cardiac Atrial Fibrillation Cardiovascular Diseases Heart Diseases Myocardial Ischemia Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dubrava University Hospital

Zagreb, 10000, Croatia

Location status: Recruiting

Location contact

Sime Manola, M.D.

CONTACT

[email protected]

About this study

Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.

In this long-term follow-up registry we plan to collect data on clinical status, standard laboratory results including lipidogram values, NTproBNP values after specific interventions (in.ex. TAVI implantation, SGLT2inh prescripition), bleeding complications, and every major cardiovascular event, including cardiovascular death and all cause death.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients implanted with CIED, or with VTE, or with ACS or with TAVI -

Exclusion criteria

non compliance, not undergoing follow-up at this center

-

Treatment and study plan

SGLT-2 inh therapy, CIED implantation, thromboaspiration,

Other

long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital

Primary outcomes

  1. cardiovascular death

    Time frame: 10 years

    death due to cardiovascular etiology during long term follow-up

  2. freedom from atrial arrhythmias

    Time frame: 10 years

    Freedom from atrial arrhythmias after PVI during mid-term folow-up (1 year) and long-term follow-up

  3. Time to revascularization

    Time frame: 10 years

    Time to revascularization during acute coronary syndrome

  4. Bleeding complications

    Time frame: 10 years

    Bleeding complications during long-term follow-up in patients prescribed with oral anticoagulation and/or antithrombotic therapy

  5. Laboratory levels of NTproBNP

    Time frame: 10 years

    Laboratory levels of NTproBNP in patients with AFib after PVI, in patients with HF prescribed with SGLT2 inhibitors, in patients with ACS after complete revasculariazation, in patients implanted with CIED

Study contacts

Contact information is provided by the study sponsor or research team.

Ivan Zeljkovic, M.D.

CONTACT

[email protected]

00385917823289

Ivana Jurin, M.D.

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Hospital Dubrava

Other

Registry information

Official study title

Cardiology Research Dubrava: Single Centre, Prospective Registry

Acronym: CaRDr

Important dates

Study start
2023
Primary completion
2033
Study completion
2033
First posted
Oct 19, 2023
Registry last updated
Mar 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.